CytoMed Therapeutics Limited

NasdaqCM GDTC

CytoMed Therapeutics Limited Return on Assets (ROA) for the year ending December 31, 2023: -25.32%

CytoMed Therapeutics Limited Return on Assets (ROA) is -25.32% for the year ending December 31, 2023, a 59.00% change year over year. Return on assets measures profitability against assets; higher ROA indicates efficient asset use and profitability.

CytoMed Therapeutics Limited Return on Assets (ROA) for the year ending December 31, 2022 was -61.75%, a -81.06% change year over year.
CytoMed Therapeutics Limited Return on Assets (ROA) for the year ending December 31, 2021 was -34.11%, a 33.00% change year over year.
CytoMed Therapeutics Limited Return on Assets (ROA) for the year ending December 31, 2020 was -50.91%, a -134.68% change year over year.
CytoMed Therapeutics Limited Return on Assets (ROA) for the year ending December 31, 2019 was -21.69%.

Key data

Date	Return on Assets (ROA)	Return on Equity (ROE)	Return on Capital Employed (ROCE)	Interest Coverage Ratio

NasdaqCM: GDTC

CytoMed Therapeutics Limited

CEO	Mr. Chee Kong Choo
IPO Date	April 14, 2023
Location	Singapore
Headquarters	1 Commonwealth Lane, No. 08-22
Employees	28
Sector	Healthcare
Industries Biotechnology 3D Printing Robotics

Description

CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers. The company's lead product candidate is CTM-N2D, which consists of expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor to improve anti-cancer cytotoxicity. It is also developing iPSC-gdNKT, which utilizes iPSC as a starting material to generate gdNKT, a synthetic hybrid of a gamma delta T cell and a NK cell; and CTM-GDT, a product candidate that consists of expanded gamma delta T cells, and exploits the multiple recognition system of gamma delta T cell to recognize and treat a range of cancers. The company was incorporated in 2018 and is headquartered in Singapore.

Key trends

Past 5 years